Table 1 Clinical background information of the Met-pa participating in this study
Patient characteristics | Â |
|---|---|
Total, N | 52 |
Age (years), mean (range) | 64 (40–83) |
Gender, N (%) | |
 Female | 26 (50%) |
 Male | 26 (50%) |
Type of cancer, N (%) | |
 Colon and rectum | 16 (31%) |
 Breast | 6 (12%) |
 Lung | 7 (13%) |
 Pancreatic | 6 (12%) |
 Gastric | 3 (6%) |
 Esophageal | 2 (4%) |
 Cervical, endometrial, ovarian | 4 (8%) |
 Renal | 3 (6%) |
 Prostate | 4 (8%) |
Metastasis location, N (%) | |
 Lung | 16 (21%) |
 Bone | 14 (18%) |
 Abdomen | 5 (7%) |
 Liver | 23 (30%) |
 Pancreas | 2 (3%) |
 Brain | 4 (5%) |
 Lymph nodes | 3 (4%) |
 Pericardial effusion | 2 (3%) |
 Omentum | 2 (3%) |
 Cervical/uterus | 4 (5%) |
 Scrotum | 1 (1%) |
Chemotherapy, N (%) | |
 5-Fluorouracil, Irinotecan, Oxaliplatin | 10 (19%) |
 Taxanes (Taxol, Paclitaxel, Docetaxel) | 5 (10%) |
 Alkylating agents (Carboplatin, Irinotecan, Cisplatin, Etopisode) | 4 (8%) |
 Antimetabolites (Trabectedin, Capecitabine, Trifluridine, Pemetrexed) | 6 (12%) |
 Inhibitor (Copanisilib, Pembrolizumab, Topotecan, Arbiraterone) | 27 (52%) |